Dianthus Therapeutics, Inc. (DNTH)
NasdaqCM · Biotechnology
Scores are generated from technical indicators for educational purposes and are not a recommendation to buy or sell.
Price history
Daily closes and volumeAI Analysis Generated from the indicator readings below. Educational only.
Dianthus Therapeutics, Inc. is trading at $88.04, down 0.19% on the session. The 50 day average sits at $104.38 and the 200 day at $81.38, which puts the stock in a uptrend. RSI is at 29.5, which reads as oversold, and MACD is bearish crossover. Volume is below average.
The nearest support is around $84.72 with resistance near $107.99, so that band frames the current range. Average daily movement is roughly $4.60, or about 5.2% of the share price, which is what any stop placement has to allow for. The overall health score of 45 out of 100 combines a trend score of 53, momentum of 28 and a risk score of 57.
Technical indicators
AI trade signals on DNTH
All signals| Date | Setup | Entry | Target | Stop | R:R | Status |
|---|---|---|---|---|---|---|
| Oct 2 | Bounce | ••.•• | ••.•• | ••.•• | 1.83:1 | Open |
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Company website